ChemMedChem · 2022 · 12 citations · 40 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyVirologyAntiviral AgentsAntiviral PharmacologyEnzyme InhibitionLead Compound DesignLead DiscoveryNatural Product Drug DiscoveryAntiviral Compound ScreeningAntiviral Natural ProductsAntiviral Structure-activity RelationshipsAntiviral TherapeuticsProtease InhibitorsViral Protease InhibitionZika Virus Screening
Abstract As the Zika virus protease is an essential and well‐established target for the development of antiviral agents, we biochemically screened for inhibitors using a purified recombinantly expressed form of this enzyme. As a result, we were able to identify 10 new Zika virus protease inhibitors. These compounds are natural products and showed strong inhibition in the biochemical assays. Inhibitory constants values for the compounds ranged from 5 nM to 8 μM. Among the most potent inhibitors are flavonoids like irigenol hexa‐acetate (K i =0.28 μM), katacine (K i =0.26 μM), theaflavin gallate (K i =0.40 μM) and hematein (K i =0.33 μM). Inhibitors from other groups of natural products include sennoside A (K i =0.19 μM) and gossypol (K i =0.70 μM). Several of the obtained compounds are known for their beneficial health effects and have acceptable pharmacokinetic characteristics. Thus, they could be of interest as lead compounds for the development of important and essential Zika antiviral drugs.
40
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin, Xiaoyu Du, Yechun Xu et al. · Nature · 2020 · 4.5K citations · Full text
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai, Bing Zhang, Xia-Ming Jiang et al. · Science · 2020 · 1.6K citations · Full text